Pell Bio-Med Technology Co., Ltd. (TPE:6949)

Market Cap	20.79B
Revenue (ttm)	29.99M
Net Income (ttm)	-373.72M
Shares Out	58.57M
EPS (ttm)	-6.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82,185
Average Volume	145,853
Open	359.50
Previous Close	354.50
Day's Range	352.50 - 361.50
52-Week Range	78.50 - 505.00
Beta	n/a
RSI	41.27
Earnings Date	Mar 13, 2026

About Pell Bio-Med Technology

Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the development of cell culture technologies and techniques for therapeutic applications. Its commercial products include good tissue practice laboratory infrastructure, adipose-derived stem cells (ADSC) for regenerative medicine, and CIK and DC-CIK against cancers. The company also develops medicines for various types of cancers, cell immunotherapy, and stem cell regenerative therapy technologies. In addition, it engages in the research and development of chimeric antigen rece...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6949

Financial Performance

In 2024, Pell Bio-Med Technology's revenue was 19.63 million, an increase of 8.86% compared to the previous year's 18.03 million. Losses were -389.42 million, -2.34% less than in 2023.